No Data
Lyell Immunopharma Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After the Company Announced Yesterday It Will Present Clinical Data From Its Phase 1-2 Trial of IMPT-314 CAR T-cell Therapy for B-cell Lymphoma at ASH 2024.
Lyell Announces Presentation of Initial Clinical Data From the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
Express News | Lyell Announces Presentation of Initial Clinical Data From the Phase 1-2 Clinical Trial of Impt-314 for the Treatment of B-Cell Lymphoma at the 2024 American Society of Hematology (Ash) Annual Meeting
Lyell Immunopharma Names Sumant Ramachandra to Board >LYEL
Lyell Immunopharma Expects Its Cash Balance Will Fund Ops Into 2027 >LYEL
Express News | Lyell Immunopharma Completes Acquisition of Immpact Bio
No Data
No Data